+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

IntegraGen SA (ALINT) - Product Pipeline Analysis, 2018 Update

  • PDF Icon

    Company Profile

  • 27 Pages
  • July 2018
  • GlobalData
  • ID: 4400028
IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, genomic research tools and solutions to microbiologic researchers. It also offers DNA extraction, management samples, study design, strategy, selection markers, tagging, biostatistics analysis and bioinformatics analysis of sequence data services, among others. IntegraGen develops miR-31-3p, a microRNA biomarker for metastatic colorectal and lung cancer. The company offers services in the fields of pharmacogenetics, cytogenetics, epigenetics and agriculture. It caters to patients, clinicians and researchers. The company has operations in France and the US. IntegraGen is headquartered in Paris, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

  • The report analyzes all pipeline products in development for the company IntegraGen SA

  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

  • The report provides detailed description of products in development, technical specification and functions

  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

  • To formulate effective Research & Development strategies

  • Develop market-entry and market expansion strategies

  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • IntegraGen SA Company Overview
  • IntegraGen SA Company Snapshot
  • IntegraGen SA Pipeline Products and Ongoing Clinical Trials Overview
  • IntegraGen SA - Pipeline Analysis Overview
  • IntegraGen SA - Key Facts
  • IntegraGen SA - Major Products and Services
  • IntegraGen SA Pipeline Products by Development Stage
  • IntegraGen SA Pipeline Products Overview
  • Biomarker-Based Diagnostic Test - hsa-miR-31-3p - Lung Cancer
  • Biomarker-Based Diagnostic Test - hsa-miR-31-3p - Lung Cancer Product Overview
  • Diagnostic Test - Hepatocellular Carcinoma
  • Diagnostic Test - Hepatocellular Carcinoma Product Overview
  • ICE Software
  • ICE Software Product Overview
  • Laboratory Developed Test - hsa-miR-31-3p - Lung Cancer
  • Laboratory Developed Test - hsa-miR-31-3p - Lung Cancer Product Overview
  • IntegraGen SA - Key Competitors
  • IntegraGen SA - Key Employees
  • IntegraGen SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • IntegraGen SA, Recent Developments
  • Jun 01, 2018: Gopath Labs Announces North American Launch of MiR-31-3p Expression Test
  • Apr 23, 2018: IntegraGen Achieves ISO 13485:2016 Certification for the Design, Manufacturing and Distribution of In Vitro Diagnostic Kits
  • Apr 13, 2018: IntegraGen Reports 2017 Annual Results
  • Apr 12, 2018: IntegraGen Presents Positive Data from Liquid Biopsy Studies of Company’s Proprietary miRNAs during 2018 European Lung Cancer Conference
  • Jan 18, 2018: IntegraGen Launches SIRIUS and MERCURY - Big Data Tools Which Enable Ultra-Efficient Exploration of Large-Scale Genomic Data
  • Jan 09, 2018: IntegraGen Reports 2017 revenue and cash position
  • Oct 09, 2017: IntegraGen Announces miR-31-3p Publication in Oncotarget
  • Sep 29, 2017: IntegraGen Reports Financial Results for 1st Half of 2017
  • Sep 07, 2017: IntegraGen Announces CE-IVD Marking of miRpredX 31-3p Kit Which Predicts Patient Response to anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
  • Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer

List of Tables


  • IntegraGen SA Pipeline Products and Ongoing Clinical Trials Overview
  • IntegraGen SA Pipeline Products by Equipment Type
  • IntegraGen SA Pipeline Products by Indication
  • IntegraGen SA, Key Facts
  • IntegraGen SA, Major Products and Services
  • IntegraGen SA Number of Pipeline Products by Development Stage
  • IntegraGen SA Pipeline Products Summary by Development Stage
  • Biomarker-Based Diagnostic Test - hsa-miR-31-3p - Lung Cancer - Product Status
  • Biomarker-Based Diagnostic Test - hsa-miR-31-3p - Lung Cancer - Product Description
  • Diagnostic Test - Hepatocellular Carcinoma - Product Status
  • Diagnostic Test - Hepatocellular Carcinoma - Product Description
  • ICE Software - Product Status
  • ICE Software - Product Description
  • Laboratory Developed Test - hsa-miR-31-3p - Lung Cancer - Product Status
  • Laboratory Developed Test - hsa-miR-31-3p - Lung Cancer - Product Description
  • IntegraGen SA, Key Employees
  • IntegraGen SA, Subsidiaries
  • Glossary

List of Figures


  • IntegraGen SA Pipeline Products by Equipment Type
  • IntegraGen SA Pipeline Products by Development Stage

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Genfit SA
  • Cellectis SA
  • Adocia SAS